CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03480-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Somaye Noruzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms, Drug Resistance, Neoplasm, Radiation Tolerance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 201 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer presents a global health challenge with rising incidence and mortality. Despite treatment advances in cancer therapy, radiotherapy and chemotherapy remained the most common treatments for all types of cancers. However, resistance phenotype in cancer cells leads to unsatisfactory results in the efficiency of therapeutic strategies. Therefore, researchers strive to propose effective solutions to overcome treatment failure, which requires a deep knowledge of treatment-resistant mechanisms. The progression and occurrence of tumors can be attributed to gene mutation. Over the past decade, the emergence of clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9) genome editing has revolutionized cancer research. This versatile technology enables cancer modeling, manipulation of specific DNA sequences, and genome-wide screening. CRISPR/Cas9 is an effective tool for identifying radio- and chemoresistance genes and offering potential adjunctive treatments to overcome tumor recurrence after chemo- and radiotherapy. This article aims to explain the potential of the CRISPR/Cas9 system in improving the effectiveness of chemo- and radiotherapy and ultimately overcoming treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. JamialahmadiKh@mums.ac.ir.
Zitieren
APA
Noruzi, S., Mohammadi, R., & Jamialahmadi, K. (2025). CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03480-2
Vancouver
Noruzi S, Mohammadi R, Jamialahmadi K. CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03480-2
BibTeX
@article{Noruzi2025,
author = {Noruzi, Somaye and Mohammadi, Rezvan and Jamialahmadi, Khadijeh},
title = {CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03480-2}
}
EUVIMED